tradingkey.logo

Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration

ReutersDec 24, 2025 12:08 PM

- Repare Therapeutics Inc RPTX.O:

  • REPARE THERAPEUTICS ANNOUNCES ACQUISITION OF POLΘ ATPASE INHIBITOR, RP-3467, BY GILEAD SCIENCES FOR UP TO $30 MILLION IN TOTAL CONSIDERATION

  • REPARE THERAPEUTICS INC - GILEAD TO BUY RP-3467 FROM REPARE FOR UP TO $30 MILLION

  • REPARE THERAPEUTICS INC - TO RECEIVE $25 MILLION UPFRONT, $5 MILLION ON TECH TRANSFER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI